How Diabetes Medications Including GLP-1 Drugs Affect Skin Conditions

GLP-1 and GLP-1/GIP agonists have hormonal and immune effects that may benefit skin diseases like psoriasis and hidradenitis suppurativa.

Ponce, Mayra Betancourt et al.·Cutis·2025·low-moderateNarrative Review
RPEP-13077Narrative Reviewlow-moderate2025RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Narrative Review
Evidence
low-moderate
Sample
N=N/A (review)
Participants
Patients with type 2 diabetes using GLP-1 or GLP-1/GIP agonists

What This Study Found

GLP-1 and dual GLP-1/GIP agonists have immune-modulating effects that may benefit inflammatory skin diseases while also causing potential dermatologic side effects.

Key Numbers

No specific trial data reported; qualitative review of case reports and small studies.

How They Did This

Narrative review of dermatologic adverse effects and therapeutic benefits of T2DM medications.

Why This Research Matters

With millions on GLP-1 drugs, dermatologists and endocrinologists need to understand skin-related effects — both beneficial and adverse.

The Bigger Picture

The anti-inflammatory properties of GLP-1 drugs may open unexpected dermatologic applications, adding to their growing list of potential benefits.

What This Study Doesn't Tell Us

Narrative review — evidence quality varies. Most dermatologic data comes from case reports and small studies rather than large trials.

Questions This Raises

  • ?Should GLP-1 drugs be preferentially prescribed for diabetic patients with psoriasis?
  • ?What dermatologic monitoring should accompany GLP-1 therapy?

Trust & Context

Key Stat:
Dual effects GLP-1 drugs may improve inflammatory skin diseases while also causing dermatologic side effects
Evidence Grade:
Narrative review — useful clinical overview but evidence for dermatologic effects is still early-stage.
Study Age:
Published in 2025, capturing emerging observations about skin effects of newer diabetes medications.
Original Title:
Dermatologic Implications of Glycemic Control Medications for Patients with Type 2 Diabetes Mellitus.
Published In:
Cutis, 115(1), 7-13 (2025)
Database ID:
RPEP-13077

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study

Summarizes existing research without a strict systematic method.

What do these levels mean? →

Frequently Asked Questions

Can GLP-1 drugs help with skin conditions?

Early evidence suggests their anti-inflammatory effects may benefit conditions like psoriasis and hidradenitis suppurativa, though more research is needed.

Do GLP-1 drugs cause skin problems?

Some dermatologic side effects have been reported, but the drugs may also benefit certain inflammatory skin conditions — effects go both ways.

Read More on RethinkPeptides

Cite This Study

RPEP-13077·https://rethinkpeptides.com/research/RPEP-13077

APA

Ponce, Mayra Betancourt; Shields, Bridget E. (2025). Dermatologic Implications of Glycemic Control Medications for Patients with Type 2 Diabetes Mellitus.. Cutis, 115(1), 7-13. https://doi.org/10.12788/cutis.1148

MLA

Ponce, Mayra Betancourt, et al. "Dermatologic Implications of Glycemic Control Medications for Patients with Type 2 Diabetes Mellitus.." Cutis, 2025. https://doi.org/10.12788/cutis.1148

RethinkPeptides

RethinkPeptides Research Database. "Dermatologic Implications of Glycemic Control Medications fo..." RPEP-13077. Retrieved from https://rethinkpeptides.com/research/ponce-2025-dermatologic-implications-of-glycemic

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.